BioCentury | Jul 10, 2020
Finance

With record fund flows, biotech a top sector for investors heading into 3Q20

...cash. A survey in April of over 100 biotechs by BioCentury and investment management firm Sanford C. Bernstein...
BioCentury | May 2, 2020
Deals

At the end of this crisis, the biopharma ecosystem might emerge with a better landscape

...reaching that point, according to a survey last week by BioCentury and investment management firm Sanford C. Bernstein...
BioCentury | Apr 27, 2020
Product Development

Biotechs tighten belts, Hahn defends test policy: a BioCentury podcast

...Commissioner Stephen Hahn. The survey of 106 biotech companies by BioCentury and investment management firm Sanford C. Bernstein...
BioCentury | Apr 25, 2020
Finance

SURVEY: Small biotechs tighten belts, seek alternative funding to avoid low-valuation deals

...at reduced valuations. A survey of 106 biotech companies by BioCentury and investment management firm Sanford C. Bernstein...
BioCentury | Jul 30, 2018
Financial News

Biopharma analyst Anderson departs Bernstein

...Equity analyst Tim Anderson left the Sanford C. Bernstein research division of AllianceBernstein Holding L.P. (NYSE:AB) this month...
BioCentury | Jun 23, 2018
Strategy

Gawande’s Cheesecake Factory

...have barely worked.” He elaborated on the failings of high deductibles in remarks to a Sanford C. Bernstein...
BioCentury | Jan 11, 2016
Financial News

Otonomy completes follow-on

...million Price: $20 Shares after offering: 29.2 million Underwriters: BofA Merrill Lynch; Cowen; Piper Jaffray; Sanford C. Bernstein...
BioCentury | Jun 29, 2015
Financial News

Alder completes follow-on

...million Price: $44.50 Shares after offering: 42.5 million Underwriters: Credit Suisse; Leerink Partners; Wells Fargo; Sanford C. Bernstein...
BioCentury | Mar 16, 2015
Financial News

Portola Pharmaceuticals Inc completes follow-on

...2.5 million Price: $40 Shares after offering: 51.3 million Underwriters: Morgan Stanley; Credit Suisse; Cowen; Sanford C. Bernstein...
BioCentury | Feb 2, 2015
Financial News

Spark Therapeutics completes IPO

...Shares: 7 million Price: $23 Shares after offering: 23.5 million Underwriters: JPMorgan; Credit Suisse; Cowen; Sanford C. Bernstein...
Items per page:
1 - 10 of 57
BioCentury | Jul 10, 2020
Finance

With record fund flows, biotech a top sector for investors heading into 3Q20

...cash. A survey in April of over 100 biotechs by BioCentury and investment management firm Sanford C. Bernstein...
BioCentury | May 2, 2020
Deals

At the end of this crisis, the biopharma ecosystem might emerge with a better landscape

...reaching that point, according to a survey last week by BioCentury and investment management firm Sanford C. Bernstein...
BioCentury | Apr 27, 2020
Product Development

Biotechs tighten belts, Hahn defends test policy: a BioCentury podcast

...Commissioner Stephen Hahn. The survey of 106 biotech companies by BioCentury and investment management firm Sanford C. Bernstein...
BioCentury | Apr 25, 2020
Finance

SURVEY: Small biotechs tighten belts, seek alternative funding to avoid low-valuation deals

...at reduced valuations. A survey of 106 biotech companies by BioCentury and investment management firm Sanford C. Bernstein...
BioCentury | Jul 30, 2018
Financial News

Biopharma analyst Anderson departs Bernstein

...Equity analyst Tim Anderson left the Sanford C. Bernstein research division of AllianceBernstein Holding L.P. (NYSE:AB) this month...
BioCentury | Jun 23, 2018
Strategy

Gawande’s Cheesecake Factory

...have barely worked.” He elaborated on the failings of high deductibles in remarks to a Sanford C. Bernstein...
BioCentury | Jan 11, 2016
Financial News

Otonomy completes follow-on

...million Price: $20 Shares after offering: 29.2 million Underwriters: BofA Merrill Lynch; Cowen; Piper Jaffray; Sanford C. Bernstein...
BioCentury | Jun 29, 2015
Financial News

Alder completes follow-on

...million Price: $44.50 Shares after offering: 42.5 million Underwriters: Credit Suisse; Leerink Partners; Wells Fargo; Sanford C. Bernstein...
BioCentury | Mar 16, 2015
Financial News

Portola Pharmaceuticals Inc completes follow-on

...2.5 million Price: $40 Shares after offering: 51.3 million Underwriters: Morgan Stanley; Credit Suisse; Cowen; Sanford C. Bernstein...
BioCentury | Feb 2, 2015
Financial News

Spark Therapeutics completes IPO

...Shares: 7 million Price: $23 Shares after offering: 23.5 million Underwriters: JPMorgan; Credit Suisse; Cowen; Sanford C. Bernstein...
Items per page:
1 - 10 of 57